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Abstract: New waveforms have changed the field of Spinal Cord Stimulation (SCS) to optimize
therapy outcomes, among which is High-Dose SCS (HD-SCS). Missing observations are often encoun-
tered when conducting clinical trials in this field. In this study, different approaches with varying
assumptions were constructed to evaluate how conclusions may be influenced by these assumptions.
The aim is to perform a tipping point sensitivity analysis to evaluate the influence of missing data on
the overall conclusion regarding the effectiveness of HD-SCS on disability. Data from the Discover
study were used, in which 185 patients with Failed Back Surgery Syndrome were included. Disability
was evaluated before SCS and after 1, 3 and 12 months of HD-SCS. During the second, third and
fourth visit, data from 130, 114 and 90 patients were available, respectively. HD-SCS resulted in a
significant decrease in disability scores based on the analysis of observed data and with multiple
imputations. The tipping point sensitivity analysis revealed that the shift parameter was 17. Thus,
the conclusion concerning the time effect under a “missing at random” mechanism is robust when
the shift parameter for the disability score is 17. From a clinical point of view, a shift of 17 points on
disability is not very plausible. Therefore we tend to consider the conclusions drawn under “missing
at random” as being robust.
Keywords: missing data mechanisms; sensitivity analysis; multiple imputations; neuromodulation
1. Introduction
Spinal Cord Stimulation (SCS) has been established as an effective therapy to treat a
wide variety of chronic pain conditions among which patients with Failed Back Surgery
Syndrome [1], recently called Persistent Spinal Pain Syndrome Type II (PSPS T2). This
condition is characterized by persistent back and/or leg pain of unknown origin either
despite the surgical intervention or appearing after surgical intervention for spinal pain [2].
The goal of SCS is not to cure patients but rather to make chronic pain tolerable, with
benefits on function and health-related quality of life [3,4].
Initially, conventional, low-frequency SCS was provided whereby patients experi-
ence paresthesia in the painful areas [5,6]. Over the last decade, several new waveforms
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and frequencies were introduced that do not induce paresthesia [6,7]. One of those new
paresthesia-free stimulation paradigms is High-Dose SCS (HD-SCS), formerly known as
high-density SCS [8]. HD-SCS entails an increase in frequency and pulse width, along with
reduced amplitude, when compared to standard SCS [7]. Despite the absence of an exact
definition for the stimulation parameters of HD-SCS, the delivery of energy to neural tissue
is the key concept [9]. The percentage of active stimulation during a pulse cycle can be
increased up to 20–25% for the maximally available settings, at a sub sensory mode [6,7].
When evaluating the success of treatment in the field of neuromodulation, the most
prominent outcome measurement is a reduction in pain intensity [10]. However, it has
previously been demonstrated that achieving a pre-treatment goal of “reducing pain”
contributes very little to patient satisfaction in the chronic disabled back and/or neck pain
patients [11]. Moreover, achieving functional goals was more important for patient satis-
faction than a reduction in self-reported pain [11]. Additionally, a qualitative exploration
of patients’ expectations on SCS indicated that patients have more expectations than only
obtaining pain relief [12]. These studies, combined with the recent calls in the SCS literature
to focus on a combination of several outcome measurements [13–16], clearly demonstrate
that we should redefine the concept of successful treatment in SCS. Disability is one of
the factors that can be proposed as an additional self-reporting measure for evaluating
the treatment effects of SCS [15,17]. One of the most frequently used questionnaires to
evaluate disability within patients with chronic low back pain is the Oswestry Disability
Index (ODI) [18]. This questionnaire, initially developed by O’Brien in 1976, consists of ten
sections measuring pain intensity, personal care, lifting, walking, sitting, standing, sleeping,
sex life, social life, and traveling [18].
Missing observations are one of the most common but often overlooked issues that
are encountered when conducting clinical trials [19]. In 1987, Little and Rubin classified
the missing data mechanisms in three distinct categories namely missing completely at
random (MCAR; the observed responses can be seen as a random subsample of the sampled
responses, given covariates), missing at random (MAR; the probability of missingness
depends on the observed data but given these not further on the unobserved data) and
missing not at random (MNAR) [20]. A sensible starting point for clinical trials is the MAR
assumption; however, the exact missingness mechanism cannot be formally evaluated [21].
It thus becomes clear that performing analyses on incomplete data requires untestable
assumptions, pointing out the necessity of understanding the impact of these assumptions
on inferences and conclusions from the primary analysis. Sensitivity analysis entails the
creation of different models with varying assumptions and evaluating how conclusions
are influenced [22]. The aim of this study is to perform a sensitivity analysis on disability
data to evaluate the influence of missingness on the overall conclusion regarding the
effectiveness of HD-SCS on disability in patients with PSPS T2.
2. Materials and Methods
2.1. Data
Data from the Discover study, a prospective multicenter registry-based cohort study
towards the effectiveness of HD-SCS, were used in this study. The protocol was prospec-
tively registered at clinicaltrials.gov (NCT02787265) on 1 June 2016. The protocol of this
study and the main results can be found elsewhere [15,23]. Patients with PSPS T2, and a nu-
merical rating scale (NRS) score ≥5/10 for leg and/or back pain were eligible. All patients
underwent a baseline visit before lead implantation. Subsequently, patients underwent a
trial period of 4 weeks with an external neurostimulator. In case of a successful trial, in
which an average pain reduction of 50% and a reduction in pain medication use of at least
50% should be obtained, an internal pulse generator (IPG) was implanted. All patients
were implanted with a RestoreSensor, Intellis or PrimeAdanced IPG (Minneapolis, MN,
USA) and received HD-SCS with a pulse density of 25% (500 Hz and 500 sec of pulse) in
case of the RestoreSensor or Intellis and 11.7% (450 Hz and 130 sec of pulse width) in case
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of a PrimeAdvanced IPG. Finally, 3 follow-up visits took place after 1, 3, and 12 months of
HD-SCS.
The study was conducted according to the revised Declaration of Helsinki (1998). The
study protocol was approved by the ethics committee of Universitair Ziekenhuis Brussel
(B.U.N. 143201629180) and the ethics committees of each participating center. All patients
provided written informed consent before enrolment in this study.
2.2. Outcome Measurements
The primary outcome measurement for this analysis was the ODI, consisting of ten
items describing functional aspects of daily living. Each item contains six statements with
a total score of 5 [24]. A total score of 100% indicates total disability. In PSPS T2, the ODI
has a sensitivity of 0.74 and a specificity of 0.92 [25].
Current pain intensity was measured with an NRS, ranging from 0 (no pain) to 10
(maximal pain) for low back pain and leg pain separately.
2.3. Statistical Analysis
Due to the repeated measures nature of the data, longitudinal mixed models were used
to evaluate the effectiveness of HD-SCS on disability in patients with PSPS T2. Concerning
model building, a nearly saturated mean model was fitted that included all main effects,
two-way and three-way interaction terms. Age (young patients (25–45 years), middle-aged
patients (46–65 years) and older patients (66–85 years)), sex, follow-up visit (time), NRS low
back pain at baseline and NRS leg pain at baseline were used as predictors. Firstly, a model
with an unstructured covariance matrix was constructed, allowing different variances
at each visit. The necessity of random slopes and/or random intercepts was evaluated
by Restricted Maximum Likelihood (REML) estimation. Splines were also considered
(REML estimation). Secondly, an unstructured covariance matrix was compared with other
covariance structures. Model selection was performed with Akaike information criterion
(AIC) values. If the unstructured covariance matrix model did not differ significantly
from a model with more restrictive assumptions, the unstructured model was replaced.
Thirdly, the fixed part of the model was simplified by dropping unnecessary predictors
using likelihood ratio tests, starting from the interaction terms. Deletion of a predictor was
allowed if it did not affect the model (p > 0.05). If a higher-order interaction term needed to
be included, the lower interaction terms and main effects remained in the model as well.
All statistical analyses were performed in SAS 9.4 (100 SAS Campus Drive Cary, NC, USA)
with PROC MIXED.
2.4. Sensitivity Analysis
A wide variety of methods for handling missing data are available, whereby impu-
tation methods are widely applied in which the missing observation is filled up with a
plausible value [26]. A commonly used technique is the “last observation carried forward”
method whereby the missing value is imputed with the last available observation [27].
The disadvantage of such single imputation methods is that they do not account for un-
certainty, thereby provoking an underestimation of the standard error of the statistical
point estimates [28]. In addition, they are prone to sometimes severe biases. A second
and quite different type of imputation is multiple imputations in which the main idea is
to replace every missing value by a set of M ≥ 2 plausible values [29]. The vector of M
values is constructed based on repeated draws from the posterior predictive distribution
of the unobserved values given the observed ones [30]. This implies that we assume
MAR during multiple imputations because the predictive distribution of the missing data,
given the observed data, does not depend on the observed response [31]. These M values
represent the uncertainty about the value, in contrast to simple imputation strategies. By
the end of this step, all missing values are filled in with M values to generate M complete
datasets. Standard methods are applied to analyze each dataset separately where after
M inferences are then combined to withhold one inference that is properly reflecting the
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sampling variability due to missing values under the considered model [30]. Although
multiple imputations assume MAR, the exact missing mechanism cannot be formally
evaluated. In a tipping point analysis, the influence of missingness is explored on the
overall conclusion from the statistical inference by applying a wide spectrum of different
assumptions regarding the missingness mechanisms [28]. The aim is to find the “tipping
point” in the spectrum of assumptions at which conclusions from the statistical inference
will be changed [28]. Afterward, a clinical interpretation can be given to the plausibility of
the assumptions [32]. If the value of the shift parameter that changes the conclusions of
the main study inference is implausible, then greater confidence can be inferred from the
main results [29]. A tipping point that is situated at a biologically or clinically implausible
location provides evidence for the robustness of the conclusions reached under MAR.
Firstly, a dataset without missingness was created using multiple imputation strate-
gies. Two approaches were consecutively performed: (1) creation of a dataset with only
monotone missingness; (2) creation of a dataset without missingness by regression-based
imputation (PROC MI procedure). The former is achieved with a Markov Chain Monte
Carlo method using a multivariate normal model [33]. The advantage of the latter is that a
sequential approach with univariate models with a number of predictor variables is used.
This enables first imputing data from the earliest visit, whereby the outcome can then
be used as predictor for imputations at later visits [34]. The imputation model included
the previous outcomes of the dependent variable combined with covariates age and pain
intensity scores. Ten imputations were created for each missing value.
Secondly, a set of shift parameters with a progressive increased departures from MAR
(shift = 0) is applied. A wide spectrum of shifts for the values that were missing was
assumed, ranging from a decrease of −30 on the ODI up to + 30. Next, the same steps
as above were conducted to generate multiply imputed datasets, with a specified shift
parameter that adjusts the imputed values. Thereafter, the imputed datasets were analyzed
by using the same likelihood analysis as in the primary analysis (PROC MIXED procedure).
Inferences were then combined for each shift parameter until a p-value of 0.05 or higher
was revealed for the main study inference (MI ANALYZE procedure). The basis for this
analysis was the SAS macro by Yang (2013) for RCT’s, available from the SAS help center.
3. Results
3.1. Descriptive Statistics
In this study, 89 males (48.1%) and 96 females (51.9%) were included with a mean
age of 54 (SD 12.01) years. The mean ODI score at baseline was 56.99 (SD 14.97), 31.26
(SD 17.58) at 1 month, 30.64 (SD 18.52) at 3 months and 33.34 (SD 16.86) at 12 months. At
the baseline visit, data of 185 patients were available for the ODI. During the second, third
and fourth visit, data of 130, 114 and 90 patients were available, respectively.
3.2. Longitudinal Effect of HD-SCS on Disability
Overall, a decrease in average ODI scores over time was observed (Figure 1).
There seemed to be lower variability in ODI score at baseline compared to the follow-
up visits. The ODI score seemed to decrease very fast from baseline to one month of SCS,
wherefore a linear spline was added to the model. The main idea behind this concept is to
divide the time axis into a series of segments and consider a model for the trend over time
that is comprised of piecewise linear trends, with different slopes within each segment that
are tied together at fixed times (denoted as “knots”) [31]. Therefore, a knot was assumed at
the first month’s visit thanks to the creation of an additional variable “Time1” which took
the value zero when the observation occurred before the first month. Otherwise, the new
variable took the value of the current month minus one.




Figure 1. Distribution of total score on the Oswestry Disability Index (ODI) per study visit, pre-
sented with boxplots (left) and individual profile plots (right). The mean is represented by the dia-
mond, the horizontal line represents the median ODI score at each visit. 
There seemed to be lower variability in ODI score at baseline compared to the follow-
up visits. The ODI score seemed to decrease very fast from baseline to one month of SCS, 
wherefore a linear spline was added to the model. The main idea behind this concept is to 
divide the time axis into a series of segments and consider a model for the trend over time 
that is comprised of piecewise linear trends, with different slopes within each segment 
that are tied together at fixed times (denoted as “knots”) [31]. Therefore, a knot was as-
sumed at the first month's visit thanks to the creation of an additional variable “Time1” 
which took the value zero when the observation occurred before the first month. Other-
wise, the new variable took the value of the current month minus one. 
The regression coefficient estimates of the final model are presented in Table 1. 
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The regression co fficient est mates of the final model are presented in Tabl 1.
Table 1. Regression coefficient estimates and their 95% confidence intervals, based on the final model.
Variable RegressionEstimates Sta ard Error
95% Confidence
Interval Type III Test
Intercept 25.05 2.34 (20.43–29.66) p < 0.001
NRS low back 2.32 0.25 (1.82–2.81) p < 0.001
NRS leg 1.87 0.21 (1.44–2.30) p < 0.001
Time −7.68 1.37 (−10.39–−4.98) p < 0.001
Tim 1 7.61 1.40 (4.84–10.38) p < 0.001
At the baseline visit, the average ODI score is 25.05 ((95% CI: 20.43–29.66), p ≤ 0.001)
for a patient with a pain intensity score of 0 for both back and leg pain. For 95% of the
patients, the average ODI score before treatment (i.e., at baseline) vari s between 4.83 and
45.27. Per unit increase in NRS low back pain score, the average ODI score will increase
with 2.32 ((95% CI: 1.82–2.81), F = 86.73, p ≤ 0.001). For each unit increase in NRS leg
pain score, the average ODI score will increase by 1.87 units ((95% CI: 1.44–2.30), F = 75.38,
p ≤ 0.001). During the first month of HD-SCS, there is an average decrease of 7.68 ((95% CI:
4.98–10.39), F = 31.58, p ≤ 0.001) points in the ODI score. The percentage of patients that are
experiencing an average decrease in ODI score during the first month of HD-SCS is 84.7%.
From 1 month of HD-SCS onwards, an increase of 7.61 ((95% CI: 4.84–10.38), F = 29.66,
p ≤ 0.001) in ODI score is revealed per visit. The autoregressive correlation parameter of
0.6639 indicated that, for a middle-aged patient, the correlation between two visits that
were one time unit apart was 0.6639. The correlation between older patients and young
patients was 0.18 and 0.35, respectively, between two visits that were one time unit apart.
3.3. Sensitivity Analysis
Based on the previous analysis, HD-SCS was able to significantly decrease disability
scores over time in patients with PSPS T2, based on an analysis of data as observed.
However, a substantial proportion of the data was missing. Table 2 provides an overview
of the different types of missing data.
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Table 2. Overview of missingness patterns.
Type Baseline 1 Month 3 Months 12 Months Number Percentage
Completers O O O O 81 43.78%
Monotone
missingness
O O O M 30 16.22%
O O M M 17 9.19%




O O M O 2 1.08%
O M O O 2 1.08%
O M O M 1 0.54%
O M M O 5 2.70%
Abbreviations. M: missing, O: observed.
In total, 43.78% of the patients were compliant with all visits, 50.82% exhibited mono-
tone missingness and 5.4% exhibited non-monotone missingness (Table 2). Within the group
with monotone missingness, a considerable amount of patients has no follow-up measure-
ments (25.41%), 9.19% have one follow-up visit and 16.22% have two follow-up visits.
In Table 3, the main effects of the primary analysis under multiple imputations are
presented. Type III tests for time and time1 remained statistically significant in the analysis
with multiple imputations, as observed in the analysis without imputation.
Table 3. Regression coefficient estimates and their 95% confidence intervals, based on the final model
with multiple imputations.
Variable RegressionEstimates Standard Error
95% Confidence
Interval Type III Test
Intercept 25.65 2.26 (21.19–30.12) p < 0.001
NRS low back 2.27 0.23 (1.81–2.73) p < 0.001
NRS leg 1.83 0.20 (1.43–2.23) p < 0.001
Time −8.51 1.44 (−11.39–−5.63) p < 0.001
Time1 8.46 1.49 (5.49–11.43) p < 0.001
In Table 4, the results of the tipping point analysis are presented.
Table 4. Tipping point sensitivity analysis with p-values for time effects with shifts ranging from
−30 to 30.
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A shift of zero corresponds to a standard MAR-based multiple imputation analysis.
When the ODI is shifted with a value of slightly less than 18 (meaning patients with missing
values experience more disability), the conclusion becomes different from the likelihood-
based analysis. More specifically, for a two-sided error level of 0.05, the tipping point for
the shift parameter is 17 for the time effect and 18 for the time1 effect. Thus, the study
conclusion under MAR is reversed when the shift parameter is 17. This means that if the
shift parameter of 17 is plausible, the conclusion under MAR is questionable. Visually, the
results are presented in Figure 2.
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time1 effect (right).
4. Discussion
Th effectiveness outcome in this analy is was defined as a mean disab lity reduction
over time following HD-SCS as measured by the ODI. Based on a longitudinal mixed
model, the mean disa ilit reached a strong sta istical significance over time. The
d cr as in disability in PSPS T2 patients who are treated with HD-SCS was not surprising.
In a study with multicolumn SCS, a significant decrease in ODI scores was found between
baseli e and 6 months f SCS [3]. In the SENZA RCT (comparison of 10 kHz SCS to
conventional SCS for the treat ent of chronic back an leg pain), the efficacy of 10 kHz
SCS was explored whereby the ODI was measured as a secondary outcome variable. A
significant change in ODI score was revealed after 12 months [35]. The final model in
the current study contained a knot which indicated that there is a different slope from
baseline to 1 month and from 1 month onwards. The difference in slope can be explained
by habituation, since approximately 20–40% of SCS patients suffer from a decline in initial
effectiveness of SCS due to a central nervous system tolerance, as already reported in 1993
by LeDoux [36]. This decline is often reported for pain relief [37]. However, in this study,
this phenomenon was also observed for ODI. Drastic improvements in ODI scores were
visible up to 1 month, where after a slight decrease became visible from 3 months onwards.
This trend was also mentioned in a study with health-related quality of life after 6 months
of SCS [38]. This suggests that habituation might be an issue in SCS in general but also
on the level of disability, which could potentially have a major influence on the long-term
clinical effects and therefore also in terms of salvage therapy and system explants [39].
Recently, recommendations on the levels of study design, site selection, participant
selection, treatment adherence, data collection and data monitoring were created to improve
the quality of clinical trials of chronic pain treatments [40]. In clinical trials with chronic
pain patients, patient dropout is common and typically estimated at around 20% to 50%
of trial participants, depending on the medication, dosage, pain condition, follow-up
duration, and other factors [41,42]. During the last decades, more principled methods
for handling missing data have been implemented such as ignorable likelihood, multiple
imputations or weighted generalized estimating equations, whereby direct likelihood is
expected to be the most frequently used technique in chronic pain trials [42]. With only
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missing data in the outcome, maximizing the likelihood of the observed data is expected
to provide valid inference (given an appropriate choice for the covariance structure) [43].
With missing values in the dependent and independent variables, multiple imputations
is often considered the most flexible and practical approach [43]. Nevertheless, these
methods rely on strong and untestable assumptions concerning the conditional distribution
of outcomes after dropout, given the observed data [42], wherefore sensitivity analysis
should be conducted to explore whether the conclusions from the analysis under MAR are
robust [43].
In the current multicenter registry, a rather large proportion of missing data was
present wherefore a sensitivity analysis (assuming MNAR) was performed after the pri-
mary analysis, as recommended by the ICH (International Council for Harmonisation of
Technical Requirements for Pharmaceuticals for Human Use) E9 guidance on Statistical
Principles for Clinical Trials [44]. Both monotone and non-monotone missingness patterns
were observed, whereby a two-step procedure was applied to impute missing data. More
imputation techniques are available for monotone missingness [45], wherefore data were
first imputed towards monotone missingness and then in a second step towards no missing
data. From a clinical point of view, however, monotone missingness is a major issue since
no information could be retrieved concerning the underlying reason for missing data. Only
one possible sensitivity analysis was performed namely the tipping-point analysis. Within
this type of analysis, it was explored how severe departures from MAR must be in order to
reverse conclusions from the primary analysis. In this study, a shift parameter of 17 was
needed to change the main conclusions of the longitudinal mixed model. A departure of 17
is rather large, moreover, it is well above the minimal clinical important difference (MCID)
of the ODI which is estimated at 8–10 points [46–48]. In this study, the interpretation of
the magnitude of the shift parameter was based on the MCID value, indicating that the
shift parameter was almost twice the MCID value. Thus, from a clinical point of view, this
parameter is not very plausible, indicating the robustness of the results of the previously
performed statistical methods. Therefore, we can be more confident in the results obtained
with statistical methods under the MAR assumptions namely the mixed model repeated
measurements and multiple imputations; both pointing towards a significant time effect.
Another approach to interpret the magnitude of the shift parameter is to determine a
priori an acceptable range of assumptions for this specific study context with all trial team
members. Caution is needed when tipping point approaches are performed without a
clear rationale for the interpretation of the shift parameter since the results of the analysis
might (un)knowingly influence the subsequent interpretation of the sensitivity analysis [29].
Given the lack of a universally determined best MNAR method [49], one should ideally ex-
plore a variety of sensitivity analysis in order to better evaluate the consistency/robustness
of results across the various assumptions that are made with different techniques.
The Discover study was a longitudinal cohort study, exploring the effectiveness of
HD-SCS in patients with PSPS T2. This study did not evaluate the efficacy of SCS compared
to another treatment modality, which would have enabled us to differentiate the time effect
from the treatment effect.
5. Conclusions
This is the first study to report longitudinal data on disability in patients with PSPS T2
who are treated with HD-SCS. In patients with PSPS T2, HD-SCS is an effective treatment
option to decrease disability. Sensitivity analysis indicated that the results are maintained
when the shift parameter is 17. From a clinical perspective, this shift does not seem very
realistic therefore the conclusion under MAR can be considered as robust.
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